Payment overview · 2025
General Payments
$342.61
13 reported records · 8 companies
Healthcare provider profile · identity verified
Maged Ayad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, CA · NPI 1992718332
Verified facts
What the public records show
CMS Open Payments records show Maged Ayad, MD received $342.61 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 43.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.27 | 43.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.93 | 13.7% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $34.68 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.16 | 9.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.32 | 8.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.61 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.29 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.61 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.54 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.73 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $34.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 492 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 124 |
| Losartan Potassium | Losartan Potassium | 392 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 101 |
| Gabapentin | Gabapentin | 370 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 80 |
| Metformin Hcl | Metformin Hcl | 247 | 64 |
| Omeprazole | Omeprazole | 220 | 63 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 190 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 48 |
| Meloxicam | Meloxicam | 173 | 44 |
| Simvastatin | Simvastatin | 173 | 48 |
| Montelukast Sodium | Montelukast Sodium | 170 | 46 |
| Alendronate Sodium | Alendronate Sodium | 167 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 38 |
| Furosemide | Furosemide | 148 | 42 |
| Lovastatin | Lovastatin | 148 | 40 |
| Lisinopril | Lisinopril | 147 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 147 | 37 |
| Valsartan | Valsartan | 142 | 39 |
| Glipizide | Glipizide | 141 | 29 |
| Sertraline Hcl | Sertraline Hcl | 140 | 33 |
| Januvia | Sitagliptin Phosphate | 136 | 32 |
| Jardiance | Empagliflozin | 115 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 27 |
| Finasteride | Finasteride | 113 | 30 |
| Alprazolam | Alprazolam | 110 | 25 |
| Tramadol Hcl | Tramadol Hcl | 104 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Ozempic | Semaglutide | 90 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 23 |
| Azithromycin | Azithromycin | 85 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Potassium Chloride | Potassium Chloride | 84 | 22 |
| Trazodone Hcl | Trazodone Hcl | 84 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 31 |
| Allopurinol | Allopurinol | 80 | 22 |
| Donepezil Hcl | Donepezil Hcl | 80 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Eliquis | Apixaban | 79 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 19 |
| Carvedilol | Carvedilol | 77 | 19 |
| Farxiga | Dapagliflozin Propanediol | 76 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 14 |
| Temazepam | Temazepam | 68 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 17 |
| Ibuprofen | Ibuprofen | 64 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 43 |
| Lorazepam | Lorazepam | 63 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 29 |
| Celecoxib | Celecoxib | 56 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Pregabalin | Pregabalin | 52 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 14 |
| Lidocaine | Lidocaine | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 47 | suppressed |
| Vascepa | Icosapent Ethyl | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 20 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | 11 |
| Atenolol | Atenolol | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 18 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Nystatin | Nystatin | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.61 · 13 records | Novo Nordisk Inc | EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy, XYOSTED, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error